CUE (Cue Biopharma, Inc.) Stock Analysis - SEC Filings

Cue Biopharma, Inc. (CUE) is a publicly traded Healthcare sector company. As of May 21, 2026, CUE trades at $20.03 with a market cap of $86.50M and a P/E ratio of -16.45. CUE moved -1.53% today. Year to date, CUE is +77.99%; over the trailing twelve months it is +1.70%. Its 52-week range spans $4.97 to $59.67. Rallies surfaces CUE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Where can I find CUE SEC filings?

Rallies organizes CUE SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.

CUE Key Metrics

Key financial metrics for CUE
MetricValue
Price$20.03
Market Cap$86.50M
P/E Ratio-16.45
EPS$-1.21
Dividend Yield0.00%
52-Week High$59.67
52-Week Low$4.97
Volume386
Avg Volume0
Revenue (TTM)$32.73M
Net Income$-19.52M
Gross Margin0.00%

Latest CUE News

Recent CUE Insider Trades

  • Sarraf Pasha bought 4.23K (~$1.31K) on Dec 30, 2025.
  • Sarraf Pasha bought 77.15K (~$23.17K) on Dec 30, 2025.
  • Sarraf Pasha bought 86.95K (~$27.60K) on Dec 30, 2025.

CUE Analyst Consensus

CUE analyst coverage data. Average price target: $0.00.

Common questions about CUE

Where can I find CUE SEC filings?
Rallies organizes CUE SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
Does Rallies show CUE 10-K and 10-Q filings?
Rallies organizes CUE SEC filing research, including 10-K reports, 10-Q reports, company disclosures, and filing-driven context when available.
Is CUE research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CUE. It does not provide personalized investment advice.
CUE

CUE